What does Prevest Denpro do?

Prevest Denpro Ltd is a micro-cap manufacturer of dental materials, incorporated in 1999, with recent quarterly net sales of 18 Cr and net profit of 5 Cr as of March 2025. Key metrics include a P/E ratio of 31.00 and a market cap of Rs 591 Cr.

Overview: <BR>Prevest Denpro Ltd is a leading manufacturer of dental materials, operating within the Healthcare Services industry and classified as a Micro Cap company.<BR><BR>History: <BR>Prevest Denpro Limited was incorporated on May 05, 1999, with the Registrar of Companies in Jammu & Kashmir. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 18 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 591 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 31.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.21% <BR>Debt Equity: -0.62 <BR>Return on Equity: 17.23% <BR>Price to Book: 5.40 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Has Prevest Denpro declared dividend?

Prevest Denpro Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of August 30, 2024. While the company shows mixed total returns across different periods, the dividend yield is relatively low at 0.21%.

Prevest Denpro Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 30 Aug 2024<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.05%, with a dividend return of 0%, resulting in a total return of -13.05%.<BR><BR>Over the past year, the price return was 25.21%, the dividend return was 0.23%, leading to a total return of 25.44%.<BR><BR>In the 2-year period, the price return was 16.99%, the dividend return was 0.47%, culminating in a total return of 17.46%.<BR><BR>For the 3-year period, the price return stood at 60.7%, with a dividend return of 0.72%, resulting in a total return of 61.42%.<BR><BR>Over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Prevest Denpro has declared a dividend, the total returns over various periods show a mixed performance, with significant gains in the longer term but recent declines in the short term. The dividend yield remains relatively low, indicating that while dividends are being paid, they may not be a significant driver of returns for investors.

Who are the peers of the Prevest Denpro?

Prevest Denpro's peers include Vimta Labs, Tarsons Products, Suraksha Diagnostics, 3B Blackbio, and others. In terms of management risk, growth, and capital structure, Prevest Denpro shows average performance, with a 1-year return of -6.16%, better than Tarsons Products but lower than its other peers.

Peers: The peers of Prevest Denpro are Vimta Labs, Tarsons Products, Suraksha Diagno., 3B Blackbio, Sastasundar Ven., One Global Serv, Nureca, Hemant Surgical, Bilcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at One Global Serv and Hemant Surgical, while Good management risk is found at Vimta Labs, Suraksha Diagno., and the rest. Average management risk is present at Prevest Denpro, 3B Blackbio, Nureca, and the rest. Below Average management risk is noted at Tarsons Products, Sastasundar Ven., and Bilcare. Excellent growth is seen at 3B Blackbio and One Global Serv, while Good growth is found at Vimta Labs and Suraksha Diagno., with Average growth at Sastasundar Ven. and the rest. Below Average growth is noted at Prevest Denpro, Nureca, and the rest. Excellent capital structure is observed at Vimta Labs, 3B Blackbio, One Global Serv, and the rest, while Good capital structure is found at Tarsons Products and Suraksha Diagno., with Average capital structure at QMS Medical and Below Average capital structure at Bilcare.<BR><BR>Return Snapshot: One Global Serv has the highest 1-year return at 89.49%, while Tarsons Products has the lowest at -23.12%. Prevest Denpro's 1-year return is -6.16%, which is higher than Tarsons Products but lower than the returns of all other peers. Additionally, the six-month returns for Nureca, One Global Serv, and Hemant Surgical are negative.

Who are in the management team of Prevest Denpro?

As of March 2023, the management team of Prevest Denpro includes Atul Modi (Chairman & Managing Director), Namrata Modi (Whole Time Director & CFO), Sai Kalyan Surapaneni (Executive Director), Niharika Modi (Non Executive Director), Nikhil Shrikant Bobade, Sudeep Haralakatte Murthy, and Pardeep Gandotra (all Independent Non Executive Directors), and Vaibhav Munjal (Executive Director). Each member contributes to the company's governance and operational management.

As of March 2023, the management team of Prevest Denpro includes the following individuals:<BR><BR>1. Atul Modi - Chairman & Managing Director<BR>2. Namrata Modi - Whole Time Director & CFO<BR>3. Sai Kalyan Surapaneni - Executive Director<BR>4. Niharika Modi - Non Executive Director<BR>5. Nikhil Shrikant Bobade - Independent Non Executive Director<BR>6. Sudeep Haralakatte Murthy - Independent Non Executive Director<BR>7. Vaibhav Munjal - Executive Director<BR>8. Pardeep Gandotra - Independent Non Executive Director<BR><BR>Each member plays a distinct role within the organization, contributing to its governance and operational management.

Who are the top shareholders of the Prevest Denpro?

The top shareholders of Prevest Denpro include Atul Modi, the largest individual shareholder with 37.52%, and a foreign institutional investor holding 0.63%. Public shareholders include Pushpa Kumari Pankaj Prasoon at 2.47%, while individual investors collectively hold 19.54%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Prevest Denpro include the promoters, with Atul Modi being the largest individual shareholder, holding 37.52% of the shares. Additionally, there is one foreign institutional investor (FII) that holds 0.63% of the shares. Among public shareholders, Pushpa Kumari Pankaj Prasoon is the highest, with a holding of 2.47%. Individual investors collectively hold 19.54% of the company. There are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is Prevest Denpro?

As of 24th July, Prevest Denpro Ltd has a market capitalization of 696.00 Cr, with recent net sales of 63.03 Cr and a net profit of 18.16 Cr. The balance sheet for March 2024 shows shareholder's funds of 88.62 Cr and total assets of 94.82 Cr.

As of 24th July, Prevest Denpro Ltd has a market capitalization of 696.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 63.03 Cr and a Net Profit of 18.16 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 88.62 Cr and Total Assets of 94.82 Cr.

Are Prevest Denpro latest results good or bad?

Prevest Denpro's latest results show mixed performance, with a 24.18% growth in net sales and a 17.71% increase in net profit, but a decline in overall performance score to -3 raises concerns. Analysts recommend a 'Hold' on the stock due to uncertainties about the sustainability of non-operating income and the company's financial stability moving forward.

Prevest Denpro's latest financial results present a mixed picture. While the company has shown some positive trends in its quarterly performance, such as a 24.18% growth in net sales and a 17.71% increase in standalone net profit for the quarter ending March 2025, the overall score has declined to -3 from 6 over the past three months, indicating a deterioration in performance.<BR><BR>One noteworthy highlight is the non-operating income, which reached Rs 1.17 crore, the highest in the last five quarters. However, this increase raises concerns about its sustainability, as it is derived from non-business activities. Analysts are cautious, suggesting that this could lead to challenges ahead.<BR><BR>Given these factors, the stock call remains a 'Hold,' reflecting a cautious stance on the company's current performance. As the healthcare services sector evolves, Prevest Denpro's financial stability will need to be closely monitored in the upcoming quarters. Overall, while there are some positive indicators, the concerns about sustainability and the recent decline in performance suggest a more cautious outlook.

When is the next results date for Prevest Denpro?

The next results date for Prevest Denpro is 12 November 2025.

The next results date for Prevest Denpro is scheduled for 12 November 2025.

Is Prevest Denpro technically bullish or bearish?

As of November 7, 2025, the technical trend is mildly bearish, supported by bearish signals from the MACD, Dow Theory, and Bollinger Bands, despite a mildly bullish daily moving average.

As of 7 November 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD and Dow Theory indicators, both indicating a bearish outlook. The Bollinger Bands also reflect a bearish sentiment on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish view.

How has been the historical performance of Prevest Denpro?

Prevest Denpro's historical performance from March 2024 to March 2025 shows growth in net sales to 63.03 Cr, operating profit to 26.16 Cr, and profit after tax to 18.16 Cr, alongside an increase in cash reserves to 60.00 Cr, indicating overall positive financial trends.

Answer:<BR>The historical performance of Prevest Denpro shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Prevest Denpro reported net sales of 63.03 Cr, an increase from 56.43 Cr in the previous year. The total operating income also rose to 63.03 Cr from 56.43 Cr, with raw material costs slightly increasing to 14.08 Cr from 13.76 Cr. Total expenditure, excluding depreciation, grew to 40.94 Cr from 36.58 Cr, leading to an operating profit (PBDIT) of 26.16 Cr, up from 22.71 Cr. Profit before tax increased to 24.25 Cr from 21.43 Cr, resulting in a profit after tax of 18.16 Cr, compared to 16.14 Cr the previous year. The earnings per share improved to 15.13 from 13.45, while the operating profit margin slightly decreased to 35.05% from 35.18%. The profit after tax margin increased to 28.81% from 28.6%. On the balance sheet, shareholder's funds rose to 105.57 Cr from 88.62 Cr, with total assets increasing to 112.53 Cr from 94.82 Cr. Cash and cash equivalents at year-end improved to 60.00 Cr from 48.00 Cr, indicating a net cash inflow of 12.00 Cr compared to 9.00 Cr in the prior year. Overall, the financial performance of Prevest Denpro reflects growth in sales, profits, and cash reserves.

Should I buy, sell or hold Prevest Denpro?

Which are the latest news on Prevest Denpro?

Why is Prevest Denpro falling/rising?

As of 03-Dec, Prevest Denpro Ltd's stock price is at 446.00, down 3.46%, with significant declines over the past month and year. The stock has underperformed the sector and shows weak investor confidence, reflected in a 55.06% drop in delivery volume and a high Price to Book Value ratio.

As of 03-Dec, Prevest Denpro Ltd's stock price is falling, currently at 446.00, which reflects a decrease of 16.0 (-3.46%). The stock has underperformed the sector today by 3.22%, opening with a loss of 2.15% and reaching an intraday low of Rs 445.1, marking a decline of 3.66%. Over the past week, the stock has decreased by 1.65%, while it has experienced a significant drop of 14.23% over the past month, contrasting sharply with the Sensex, which has gained 1.34% in the same period.<BR><BR>The stock's performance has been consistently poor, with a year-to-date decline of 24.41% compared to the Sensex's increase of 8.92%. Additionally, the stock has generated a return of -20.46% over the past year, while the broader market has seen a modest gain of 5.27%. The company's operating profit growth rate over the last five years stands at only 10.80%, indicating poor long-term growth prospects.<BR><BR>Investor participation has also declined, with delivery volume dropping by 55.06% against the five-day average, suggesting a lack of confidence among investors. Furthermore, the stock is trading at a high Price to Book Value of 4.6, indicating an expensive valuation relative to its peers, despite a low Debt to Equity ratio. The absence of domestic mutual fund investment, which holds 0% of the company, may reflect a lack of comfort with the stock's current price or business outlook.<BR><BR>Overall, the combination of poor performance metrics, declining investor interest, and unfavorable comparisons to market benchmarks contributes to the stock's downward trajectory.

Is Prevest Denpro overvalued or undervalued?

As of December 3, 2025, Prevest Denpro is considered overvalued with a valuation grade of expensive, a PE ratio of 27.29, and a year-to-date return of -24.41%, underperforming against the Sensex's 8.92%.

As of 3 December 2025, the valuation grade for Prevest Denpro has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 27.29, an EV to EBITDA of 19.44, and a Price to Book Value of 4.63. <BR><BR>In comparison to peers, Prevest Denpro's PE ratio is lower than that of Poly Medicure, which stands at 53.52, but higher than BPL, which is at 5.92. The PEG ratio of Prevest Denpro is 1.47, indicating that while growth is priced in, it does not justify the current valuation when compared to its peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -24.41% compared to the Sensex's 8.92%.